The global targeted sequencing market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032. The growth in the global targeted sequencing market is expected to be driven by the increased use of targeted sequencing in clinical laboratories and diagnostic applications, especially in cancer research.

Market Lifecycle Stage

Targeted sequencing is a cost-effective and rapid way to detect novel and known variants in selected genetic or genomic regions. There are several different methods of DNA/RNA sequencing depending on the scale of the region being sequenced. Next-generation sequencing (NGS) is the most used method for targeted sequencing, which offers good scalability, speed, and resolution to evaluate the targeted regions of interest. Other methods include sanger sequencing and CRISPR.

The major advantage of targeted sequencing as compared to whole genome sequencing is the smaller and more manageable data sets created, which are significantly easier to analyze. Targeted next-generation sequencing focuses on specific genomic areas of interest, which is ideal for examining specific pathways or targeted resequencing. Furthermore, it is more rapid and cost-effective as compared to whole genome sequencing and allows deeper sequencing. This is a powerful and especially sensitive method of identifying gene mutations and variants, including rare variants.

Impact

• The presence of major kits/panels and assay providers of targeted sequencing has a major impact on the market. For instance, in September 2022, Thermo Fisher Scientific Inc. received FDA approval for its Oncomine Dx Target Test. This is a companion diagnostic (CDx) test for RET-fusion-positive or metastatic non-small cell lung cancer patients.
• Companies such as Danaher. (Integrated DNA Technologies, Inc.) partnered with Munich Leukaemia Laboratory (MLL)in March 2022 to join the company’s align program. The extensive sequencing portfolio of MLL combined with the company’s xGen portfolio of NGS solutions helped researchers with their NGS workflow needs.

Impact of COVID-19

In March 2019, the world was hit by a storm with the SARS-CoV-2 virus, which led to the shutting down of the entire world and everybody getting tested for the virus. As the amount of testing increased, it became important to increase the pace of testing as well. Research in sequencing the genome of the virus amplified, and governments provided lots of grants for the sequencing of the virus for syringe manufacturing.

The amplicon-based next-generation sequencing (NGS) method was widely used for genome sequencing. This is due to the ease of use and low sequencing cost of this method. This has made it the method of choice among many laboratories. COVID-19 genome sequencing is accomplished using a probe-based liquid phase hybridization technique, which can then be followed by NGS sequencing. The appeal of using target capture NGS methodology has the ability to enrich the limitless repertoire of genetic loci without the constant need to update primers and to deal with multiplexing issues that are encountered by amplicon-based approaches. That’s another reason why virome target capture NGS methodologies are being developed. The target capture-based NGS approach has another advantage, i.e., it is better at sequencing degraded samples as compared to other NGS approaches. End-to-end target-based NGS solution, which is validated for concurrent detection and sequencing characterization for respiratory viruses like SARS-CoV-2 and other respiratory pathogens, is a powerful tool for genomic surveillance in the post-COVID-19 era and can play a crucial role in the timely generation and dissemination of the genomic data.

Market Segmentation

Segmentation 1: by Product Type

• Instruments
• Kits/Panels and Assays
• Services
• Other Product Types

The global targeted sequencing market in product type is expected to be dominated by services segment during the forecast period 2022-2032. This is due to the increasing use of targeted sequences by small and mid-sized companies for whom opting for services is cheaper than purchasing sequencing instruments.

Segmentation 2: by Target Enrichment Method

• Hybridization Capture
• Amplicon Sequencing
• Other Target Enrichment Methods

The target enrichment method segment is expected to be dominated by the amplicon sequencing segment during the forecast period 2022-2032. This is because amplicon sequencing is an older technology and is currently more trusted, whereas hybridization capture is faster and more efficient, and thus, the segment is expected to grow at a higher CAGR in the coming years.

Segmentation 3: by Type of Target Capture

• Targeted DNA Sequencing
• Targeted RNA Sequencing
• Other Types of Target Capture

The global targeted sequencing market by type of target capture is expected to be dominated by targeted DNA sequencing segment during the forecast period 2022-2032. This is due to easy analysis and faster results when using targeted DNA sequencing segment.

Segmentation 4: by Application

• Oncology
• Reproductive Health
• Hereditary Diseases
• Neurological Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Rare Diseases
• Other Applications

The oncology segment is expected to dominate the market during the forecast period 2022-2032. This growth in this segment is attributed to the increasing use of targeted sequencing in clinical applications, especially w.r.t. cancer panels.

Segmentation 5: by End User

• Diagnostic and Clinical Laboratories
• Academic and Research Institutions
• Pharmaceutical and Biotech Companies
• Other End Users

Academic and research institutions is expected to dominate the end user segment in the market during the forecast period 2022-2032. However, the diagnostic and clinical laboratories segment is supposed to grow with the fastest CAGR during the forecast period. This is due to the increasing use of targeted sequencing in clinical applications as more kits/panels, and assays get FDA approvals.

Segmentation 6: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World (RoW)

North America is expected to dominate the global targeted sequencing market with a revenue of $1,413.4 million in 2021. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 15.27% during the forecast period 2022-2032.

Recent Developments in Global Targeted Sequencing Market

• In August 2022, QIAGEN N.V. launched its QIAseq targeted DNA pro panels and the QIAseq UPXome RNA library kit as an expansion of its next-generation sequencing (NGS) portfolio. Both these launches lead to the growth of the company’s sequencing product portfolio.
• In September 2022, BGI Group (MGI Tech Co., Ltd.) launched its DNBSEQ-G99, which is a mid to low-range throughput sequencer. This makes this sequencer especially suitable for targeted gene sequencing, small gene sequencing, and high and rapid-quality data output.
• In June 2022, Agilent Technologies, Inc. announced its collaboration with the Amazon Elastic Compute Cloud (Amazon EC2) G5g powered by Amazon Web Services (AWS) Graviton2 processors. The NVIDIA T4G Tensor Core GPUs, combined with NVIDIA Clara Parabricks’ advanced genomics capabilities, improved Agilent Technologies, Inc.’s cloud-native Alissa Reporter software. This collaboration is expected to streamline the company’s SureSelect family NGS assays, which comprise a wide range of custom and catalog panels.
• In June 2022, Danaher. (Integrated DNA Technologies, Inc.) made an agreement with Beckman Coulter, Inc. Life Sciences for the distribution of its Biomek NGenius Next Generation Sequencing Library Prep System. This deal helped make high-performance NGS solutions more accessible to laboratories.

Demand – Drivers and Limitations

Following are the demand drivers for the global targeted sequencing market:

• Rising Need for Sequencing at Greater Depth
• Lower Cost and Data Burden of Targeted Sequencing When Compared to Whole Genome Sequencing
• Increase in Cancer Prevalence

The market is expected to face some limitations too due to the following challenges:

• Lack of Knowledge About New Genes and Biomarkers
• Lack of High Complexity Genomic Testing Centers in High Potential Markets

How can this report add value to an organization?

Product/Innovation Strategy: The report considers both products and services-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of specific biomarkers related to various diseases are increasing researchers’ trust in targeted sequencing.

Growth/Marketing Strategy: The key components in targeted sequencing are the target capture methods and various disease panels. The advancements in target capture methods like hybridization capture are reducing the cost and increasing the efficiency of this technique. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for targeted sequencing of specific disease types.

Competitive Strategy: The key players in the global targeted sequencing market have been analyzed and profiled in the study, consisting of both product-based and service-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global targeted sequencing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.

The top segment players leading the market include targeted sequencing instruments, kits/panels and assays, services, and other product types providers. Targeted sequencing instrument providers constitute around 10.20% of the presence in the market, kits/panels and assays constitute 24.81% of the market, services providers constitute about 58.53% of the market, and other product types constitute 6.47% of the targeted sequencing market.

Key Companies Profiled

• Agilent Technologies, Inc.
• Azenta US, Inc. (GENEWIZ)
• BGI Group (MGI Tech Co., Ltd.)
• CD Genomics
• Daicel Corporation (Daicel Arbor Biosciences)
• Danaher. (Integrated DNA Technologies, Inc.)
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• LGC Limited (LGC Biosearch Technologies)
• PacBio.
• PerkinElmer Inc.
• Psomagen
• QIAGEN N.V.
• Takara Bio Inc.
• Tecan Trading AG
• Thermo Fisher Scientific Inc.
• Twist Bioscience.

Table of Contents

1 Markets

1.1 Inclusion and Exclusion Criteria
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Global Targeted Sequencing Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling

2 Market Overview

2.1 Market Overview
2.1.1 Market Definition
2.1.2 Market Footprint and Growth Potential
2.1.3 Future Potential
2.1.4 Comparison of Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing Methods
2.1.5 Evolution of Targeted Sequencing (Sanger Sequencing vs. NGS)
2.1.5.1 First-Generation Sequencing
2.1.5.2 Second-Generation Sequencing (Next-Generation Sequencing)
2.1.5.3 Third-Generation Sequencing
2.1.6 COVID-19 Impact on Targeted Sequencing Market
2.1.6.1 Impact on Research and Clinical Operations
2.1.6.2 COVID-19 Impact: Current Scenario of the Market

3 Industry Analysis

3.1 Legal Requirements
3.1.1 Legal Requirements and Framework in the U.S.
3.1.2 U.S. FDA Published Guidance
3.1.3 U.S. FDA Regulations
3.1.4 Legal Requirements Framework in Europe
3.1.5 Legal Requirements and Framework in Asia-Pacific
3.1.5.1 China
3.1.5.2 Japan
3.1.5.2.1 Pharmaceuticals and Medical Devices Agency (PMDA)
3.1.5.2.2 Ministry of Health, Labour and Welfare (MHLW)
3.1.5.3 India
3.2 Patent Analysis
3.2.1 Patent Filing Trend
3.2.2 Patent Analysis (by Year)
3.2.3 Patent Analysis (by Country)
3.2.4 Patent Analysis (by Region)

4 Market Dynamics

4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Rising Need for Sequencing at Greater Depth
4.3.2 Lower Cost and Data Burden of Targeted Sequencing When Compared to Whole Genome Sequencing
4.3.3 Increase in Cancer Prevalence
4.4 Market Challenges
4.4.1 Lack of Knowledge About New Genes and Biomarkers
4.4.2 Lack of High Complexity Genomic Testing Centers in High Potential Markets
4.5 Market Opportunities
4.5.1 Increasing Use in Clinical Research and Trials for Better Disease Pathogenesis and/or Clinical Relevance
4.5.2 Rising Adoption of Targeted Sequencing in Targeted Therapeutics

5 Competitive Landscape

5.1 Overview
5.2 Corporate Strategies
5.2.1 Mergers and Acquisitions
5.2.2 Synergistic Activities
5.3 Business Strategies
5.3.1 Product Launches/Upgradations
5.3.2 Business Expansion and Funding
5.4 Supply Chain Analysis
5.4.1 Key Entities in Supply Chain
5.5 Market Share Analysis (by Company)
5.6 Growth Share Analysis
5.6.1 Growth Share Analysis (by Application)
5.6.2 Growth Share Analysis (by End User)

6 Global Targeted Sequencing Market (by Product Type), ($Million), 2021-2032

6.1 Overview
6.2 Services
6.3 Kits/Panels and Assays
6.4 Instruments
6.5 Other Product Types

7 Global Targeted Sequencing Market (By Target Enrichment Method), ($Million), 2021-2032

7.1 Overview
7.2 Amplicon Sequencing
7.3 Hybridization Capture
7.4 Other Target Enrichment Methods

8 Global Targeted Sequencing Market (by Type of Target Capture), $Million, 2021-2032

8.1 Overview
8.2 Targeted DNA Sequencing
8.2.1 Targeted Methyl Sequencing
8.3 Targeted RNA Sequencing
8.3.1 Targeted Metagenomic Sequencing
8.4 Other Types of Target Capture

9 Global Targeted Sequencing Markets (by Application), $Million, 2021-2032

9.1 Overview
9.2 Oncology
9.2.1 Solid Tumor
9.2.2 Liquid Biopsy
9.2.3 Minimal Residual Disease Testing
9.2.4 Circulating Tumor Cell (CTC) Analysis
9.3 Infectious Diseases
9.4 Cardiovascular Diseases
9.5 Reproductive Health
9.5.1 Carrier Screening
9.5.2 Non-Invasive Prenatal Testing
9.5.3 Preimplantation Genetic Diagnosis (PGD)
9.5.4 Newborn Screening
9.6 Rare Diseases
9.7 Neurological Disorders
9.8 Hereditary Diseases
9.9 Other Applications

10 Global Targeted Sequencing Market (By End User), ($Million), 2021-2032

10.1 Overview
10.1.1 Academic and Research Institutions
10.1.2 Pharmaceutical and Biotech Companies
10.1.3 Diagnostic and Clinical Laboratories
10.1.4 Other End Users

11 Global Targeted Sequencing Market, by Region, $Million, 2021-2032

11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest-of-Asia-Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World (RoW)

12 Company Profiles

12.1 Overview
12.2 Market Value Chain of Targeted Sequencing Market
12.3 Agilent Technologies, Inc.
12.3.1 Company Overview
12.3.2 Role of Agilent Technologies, Inc. in the Global Targeted Sequencing Market
12.3.3 Key Customers of the Company
12.3.4 Key Competitors of the Company
12.3.5 Financials
12.3.6 Key Insights about the Financial Health of the Company
12.3.7 Corporate Strategies
12.3.7.1 Synergistic Activities
12.3.8 Business Strategies
12.3.8.1 Business Expansion and Funding
12.3.9 Analyst Perspective
12.4 Azenta US, Inc. (GENEWIZ)
12.4.1 Company Overview
12.4.2 Role of Azenta US, Inc. in the Global Targeted Sequencing Market
12.4.3 Key Customers of the Company
12.4.4 Key Competitors of the Company
12.4.5 Financials
12.4.6 Key Insights about the Financial Health of the Company
12.4.7 Corporate Strategies
12.4.7.1 Synergistic Activities
12.4.8 Business Strategies
12.4.8.1 Business Expansion and Funding
12.4.9 Analyst Perspective
12.5 BGI Group (MGI Tech Co., Ltd.)
12.5.1 Company Overview
12.5.2 Role of BGI Group in the Global Targeted Sequencing Market
12.5.3 Key Competitors of the Company
12.5.4 Business Strategies
12.5.5 Analyst Perspective
12.6 CD Genomics
12.6.1 Company Overview
12.6.2 Role of CD Genomics in the Global Targeted Sequencing Market
12.6.3 Key Competitors of the Company
12.6.4 Business Strategies
12.6.4.1 Product Launches and Upgradations
12.6.5 Analyst Perspective
12.7 Daicel Corporation (Daicel Arbor Biosciences)
12.7.1 Company Overview
12.7.2 Role of Daicel Corporation (Daicel Arbor Biosciences) in the Global Targeted Sequencing Market
12.7.3 Key Customers of the Company
12.7.4 Key Competitors of the Company
12.7.5 Financials
12.7.6 Key Insights about the Financial Health of the Company
12.7.7 Corporate Strategies
12.7.7.1 Mergers and Acquisitions
12.7.7.2 Synergistic Activities
12.7.8 Analyst Perspective
12.8 Danaher. (Integrated DNA Technologies, Inc.)
12.8.1 Company Overview
12.8.2 Role of Danaher. in the Global Targeted Sequencing Market
12.8.3 Key Customers of the Company
12.8.4 Key Competitors of the Company
12.8.5 Financials
12.8.6 Key Insights about the Financial Health of the Company
12.8.7 Corporate Strategies
12.8.7.1 Mergers and Acquisitions
12.8.7.2 Synergistic Activities
12.8.8 Business Strategies
12.8.8.1 Product Launch/ Approval
12.8.8.2 Funding and Expansion
12.8.9 Analyst Perspective
12.9 F. Hoffmann-La Roche Ltd
12.9.1 Company Overview
12.9.2 Role of F. Hoffmann-La Roche Ltd in the Global Targeted Sequencing Market
12.9.3 Key Competitors of the Company
12.9.4 Financials
12.9.5 Key Insights about the Financial Health of the Company
12.9.6 Corporate Strategies
12.9.6.1 Mergers and Acquisitions
12.9.6.2 Synergistic Activities
12.9.7 Business Strategies
12.9.7.1 Product Launches and Upgradations
12.9.8 Analyst Perspective
12.1 Illumina, Inc.
12.10.1 Company Overview
12.10.2 Role of Illumina, Inc. in the Global Targeted Sequencing Market
12.10.3 Key Competitors of the Company
12.10.4 Financials
12.10.5 Key Insights about the Financial Health of the Company
12.10.6 Corporate Strategies
12.10.6.1 Synergistic Activities
12.10.7 Business Strategies
12.10.7.1 Product Launches and Upgradations
12.10.7.2 Funding and Expansion
12.10.8 Analyst Perspective
12.11 LGC Limited (LGC Biosearch Technologies)
12.11.1 Company Overview
12.11.2 Role of LGC Limited (LGC Biosearch Technologies) in the Global Targeted Sequencing Market
12.11.3 Key Competitors of the Company
12.11.4 Financials
12.11.5 Key Insights about the Financial Health of the Company
12.11.6 Corporate Strategies
12.11.6.1 Mergers and Acquisitions
12.11.6.2 Synergistic Activities
12.11.7 Analyst Perspective
12.12 PacBio.
12.12.1 Company Overview
12.12.2 Role of PacBio. in the Global Targeted Sequencing Market
12.12.3 Key Customers of the Company
12.12.4 Key Competitors of the Company
12.12.5 Financials
12.12.6 Key Insights about the Financial Health of the Company
12.12.7 Corporate Strategies
12.12.7.1 Mergers and Acquisitions
12.12.7.2 Synergistic Activities
12.12.8 Business Strategies
12.12.8.1 Product Launches and Upgradations
12.12.9 Analyst Perspective
12.13 PerkinElmer Inc.
12.13.1 Company Overview
12.13.2 Role of PerkinElmer Inc. in the Global Targeted Sequencing Market
12.13.3 Key Customers of the Company
12.13.4 Key Competitors of the Company
12.13.5 Financials
12.13.6 Key Insights about the Financial Health of the Company
12.13.7 Corporate Strategies
12.13.7.1 Synergistic Activities
12.13.8 Business Strategies
12.13.8.1 Product Launches and Upgradations
12.13.9 Analyst Perspective
12.14 Psomagen
12.14.1 Company Overview
12.14.2 Role of Psomagen in the Global Targeted Sequencing Market
12.14.3 Key Customers of the Company
12.14.4 Key Competitors of the Company
12.14.5 Financials
12.14.6 Corporate Strategies
12.14.6.1 Synergistic Activities
12.14.7 Analyst Perspective
12.15 QIAGEN N.V.
12.15.1 Company Overview
12.15.2 Role of QIAGEN N.V. in the Global Targeted Sequencing Market
12.15.3 Key Customers of the Company
12.15.4 Key Competitors of the Company
12.15.5 Financials
12.15.6 Key Insights about the Financial Health of the Company
12.15.7 Corporate Strategies
12.15.7.1 Synergistic Activities
12.15.8 Business Strategies
12.15.8.1 Product Launches and Upgradations
12.15.9 Analyst Perspective
12.16 Takara Bio Inc.
12.16.1 Company Overview
12.16.2 Role of Takara Bio Inc. in the Global Targeted Sequencing Market
12.16.3 Key Customers of the Company
12.16.4 Key Competitors of the Company
12.16.5 Financials
12.16.6 Key Insights about the Financial Health of the Company
12.16.7 Analyst Perspective
12.17 Tecan Trading AG
12.17.1 Company Overview
12.17.2 Role of Tecan Trading AG in the Global Targeted Sequencing Market
12.17.3 Key Customers of the Company
12.17.4 Key Competitors of the Company
12.17.5 Financials
12.17.6 Key Insights about the Financial Health of the Company
12.17.7 Corporate Strategies
12.17.7.1 Synergistic Activities
12.17.8 Business Strategies
12.17.8.1 Product Launches and Upgradations
12.17.9 Analyst Perspective
12.18 Thermo Fisher Scientific Inc.
12.18.1 Company Overview
12.18.2 Role of Thermo Fisher Scientific Inc. in the Global Targeted Sequencing Market
12.18.3 Key Customers of the Company
12.18.4 Key Competitors of the Company
12.18.5 Financials
12.18.6 Key Insights about the Financial Health of the Company
12.18.7 Corporate Strategies
12.18.7.1 Synergistic Activities
12.18.8 Corporate Strategies
12.18.8.1 Synergistic Activities
12.18.9 Business Strategies
12.18.9.1 Product Launches and Upgradations
12.18.9.2 Funding and Expansion
12.18.10 Analyst Perspective
12.19 Twist Bioscience.
12.19.1 Company Overview
12.19.2 Role of Twist Bioscience. in the Global Targeted Sequencing Market
12.19.3 Key Customers of the Company
12.19.4 Key Competitors of the Company
12.19.5 Financials
12.19.6 Key Insights about the Financial Health of the Company
12.19.7 Corporate Strategies
12.19.7.1 Synergistic Activities
12.19.8 Business Strategies
12.19.8.1 Product Launches and Upgradations
12.19.9 Analyst Perspective
12.2 Emerging Companies
12.20.1 MedGenome
12.20.2 Novogene Co, Ltd.
12.20.3 Paragon Genomics, Inc.
12.20.4 Sage Science, Inc.
12.20.5 Zymo Research Corporation.

List of Figures

Figure 1: Global Targeted Sequencing Market, $Million, 2021 and 2032
Figure 2: Global Targeted Sequencing Market Segmentation
Figure 3: Global Targeted Sequencing Market (by Product Type), $Million, 2021-2032
Figure 4: Global Targeted Sequencing Market (by Target Enrichment Method), $Million, 2021-2032
Figure 5: Global Targeted Sequencing Market (by Type of Target Capture), $Million, 2021-2032
Figure 6: Global Targeted Sequencing Market (by Application), $Million, 2021-2032
Figure 7: Global Targeted Sequencing Market (by End User), $Million, 2021-2032
Figure 8: Global Targeted Sequencing Market (by Region)
Figure 9: Global Targeted Sequencing Market Segmentation
Figure 10: Global Targeted Sequencing Market: Research Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: Comparison between Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing Methods
Figure 15: Whole Genome Sequencing
Figure 16: Whole Exome Sequencing
Figure 17: Targeted Sequencing
Figure 18: Evolution of Targeted Sequencing Over the Three Generations
Figure 19: FDA’s Regulatory Insight System
Figure 20: Global Targeted Sequencing Market, Patent Analysis (by Year), January 2020-December 2022
Figure 21: Global Targeted Sequencing Market, Patent Analysis (by Country), January 2020-December 2022
Figure 22: Global Targeted Sequencing Market, Patent Analysis (by Region), January 2020-December 2022
Figure 23: Global Targeted Sequencing Market Dynamics
Figure 24: Global Cancer Deaths between 2010-2019
Figure 25: Share of Key Developments, January 2020-December 2022
Figure 26: Share of Mergers and Acquisitions (by Company), January 2019-December 2022
Figure 27: Share of Synergistic Activities (by Company), January 2019-December 2022
Figure 28: Share of Product Launches/Upgradations (by Company), January 2019-December 2022
Figure 29: Share of Business Expansion and Funding Activities (by Company), January 2019-December 2022
Figure 30: Targeted Sequencing Supply Chain Analysis
Figure 31: Market Share Analysis of Global Targeted Sequencing Market (by Company), 2021
Figure 32: Growth Share Analysis for Global Targeted Sequencing Market (by Application), 2021
Figure 33: Growth Share Analysis for Global Targeted Sequencing Market (by End User), 2021
Figure 34: Evolution of Biological Foundations’ Dominance over Time
Figure 35: Global Targeted Sequencing Market (by Product Type)
Figure 36: Global Targeted Sequencing Market (by Product Type), $Million, 2021 and 2032
Figure 37: Sequencing Services Workflow
Figure 38: Global Targeted Sequencing Market (Services), $Million, 2021-2032
Figure 39: Global Targeted Sequencing Market (Kits/Panels and Assays), $Million, 2021-2032
Figure 40: Global Targeted Sequencing Market (Instruments), $Million, 2021-2032
Figure 41: Global Targeted Sequencing Market (Other Product Types), $Million, 2021-2032
Figure 42: Global Targeted Sequencing Market (by Target Enrichment Method)
Figure 43: Global Targeted Sequencing Market (by Target Enrichment Method), $Million, 2021 and 2032
Figure 44: Workflow of Amplicon Sequencing
Figure 45: Global Targeted Sequencing Market (Amplicon Sequencing), $Million, 2021-2032
Figure 46: Hybridization Capture Workflow
Figure 47: Global Targeted Sequencing Market (Hybridization Capture), $Million, 2021-2032
Figure 48: Global Targeted Sequencing Market (Other Target Enrichment Methods), $Million, 2021-2032
Figure 49: Global Targeted Sequencing Market (by Type of Target Capture)
Figure 50: Global Targeted Sequencing Market (by Type of Target Capture), $Million, 2021 and 2032
Figure 51: Global Targeted Sequencing Market (Targeted DNA Sequencing), $Million, 2021-2032
Figure 52: Targeted Methyl Sequencing Workflow
Figure 53: Targeted RNA Sequencing Workflow
Figure 54: Global Targeted Sequencing Market (Targeted RNA Sequencing), $Million, 2021-2032
Figure 55: Global Targeted Sequencing Market (Other Types of Target Capture), $Million, 2021-2032
Figure 56: Global Targeted Sequencing Market (by Application)
Figure 57: Global Targeted Sequencing Market (by Application), $Million, 2021 and 2032
Figure 58: Global Targeted Sequencing Market (Oncology), $Million, 2021-2032
Figure 59: Global Targeted Sequencing Market (Infectious Diseases), $Million, 2021-2032
Figure 60: Global Targeted Sequencing Market (Cardiovascular Diseases), $Million, 2021-2032
Figure 61: Global Targeted Sequencing Market (Reproductive Health), $Million, 2021-2032
Figure 62: Global Targeted Sequencing Market (Rare Diseases), $Million, 2021-2032
Figure 63: Global Targeted Sequencing Market (Neurological Disorders), $Million, 2021-2032
Figure 64: Global Targeted Sequencing Market (Hereditary Diseases), $Million, 2021-2032
Figure 65: Global Targeted Sequencing Market (Other Applications), $Million, 2021-2032
Figure 66: Global Targeted Sequencing Market (by End User)
Figure 67: Global Targeted Sequencing Market (by End User), $Million, 2021-2032
Figure 68: Global Targeted Sequencing Market (Academic and Research Institutes), $Million, 2021-2032
Figure 69: Global Targeted Sequencing Market (Pharmaceutical and Biotech Companies), $Million, 2021-2032
Figure 70: Global Targeted Sequencing Market (Diagnostic and Clinical Laboratories), $Million, 2021-2032
Figure 71: Global Targeted Sequencing Market (Other End Users), $Million, 2021-2032
Figure 72: Global Targeted Sequencing Market (by Region)
Figure 73: Global Targeted Sequencing Market (by Region), $Million, 2021-2032
Figure 74: North America Targeted Sequencing Market, $Million, 2021-2032
Figure 75: North America: M-arket Dynamics
Figure 76: North America Targeted Sequencing Market (by Country), $Million, 2021-2032
Figure 77: U.S. Targeted Sequencing Market, $Million, 2021-2032
Figure 78: Canada Targ

The post Targeted Sequencing Market – A Global and Regional Analysis: Focus on Product Type, Target Enrichment Method, Type of Target Capture, Application, End User, and Region Analysis – Analysis and Forecast, 2022-2032 first appeared on CRI Report.

Market Segmentation

• Workflow – Upstream Biomanufacturing and Downstream Biomanufacturing
• Product – Continuous Upstream Biomanufacturing Products, Single-Use Upstream Biomanufacturing Products, and Downstream Biomanufacturing Products
• Medical Application – Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Other Applications
• End User – Biopharmaceutical Companies, CMOs/CDMOs, Research Institutions

Regional Segmentation

• North America – U.S. and Canada
• Europe – U.K., Germany, France, Italy, Spain, Ireland, Switzerland, Russia and Rest-of-Europe
• Asia Pacific – China, Japan, India, South Korea, Australia, Singapore and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, Argentina and Rest-of-Latin America
• Rest-of-the-World

Market Growth Drivers

• Increasing biologics and biosimilars approvals
• Growing trend among biomanufacturing vendors to integrate automation technologies
• Boosting bioproduction workflow while reducing cost, time, and labor

Market Challenges

• Complex production steps, process operational complexity, risk of product contamination, maintenance of production efficiency, and validation challenges
• Lack of skilled professionals
• Unharmonized manufacturing standards and lack of knowledge and skilled labor in middle-income and low-income countries

Market Opportunities

• Increasing development and commercialization of digital bioreactors
• Increasing Investment in R&D and rapid development of the biopharmaceutical industry

Key Companies Profiled

Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Guérin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd., Solaris Biotechnology Srl., Thermo Fisher Scientific Inc., ZETA GmbH

Key Questions Answered in this Report:

• What are the key trends of the global next-generation biomanufacturing market? How is the market evolving, and what is its future scope?
• What is the role of automation in biomanufacturing?
• What are the major drivers, challenges, and opportunities of the global next-generation biomanufacturing market?
• What is the regulatory framework of the global next-generation biomanufacturing market?
• What is the market share of each of the players offering products for next-generation biomanufacturing? What are the key strategies implemented by the major players to sustain the competition of the global next-generation biomanufacturing market?
• What was the market size of the global next-generation biomanufacturing market in 2020, and what is the anticipated market size in 2031? What is the expected growth rate of the global next-generation biomanufacturing market during the forecast period 2021-2031?
• What are the different next-generation biomanufacturing products used in the medical field? Which product segment is expected to observe the highest CAGR in the market during the forecast period 2021-2031?
• What are the key medical applications of the global next-generation biomanufacturing market? Which application type is expected to witness the highest growth rate during the forecast period of 2021-2031?
• Who are the key end users for the global next-generation biomanufacturing market? What was the market share held by each end user in the global next-generation biomanufacturing market in 2020? What is the expected growth rate and market share by 2031?
• What was the market value of the leading segments and sub-segments of the global next-generation biomanufacturing market in 2020, and what are the values expected to be in 2031? What are the different macro- and micro-economic factors influencing the growth of the market?
• Which region dominated the global next-generation biomanufacturing market in 2020? Which geography can be the target market for significant expansion of key companies for different next-generation biomanufacturing products?
• What are the key countries contributing significantly toward the growth of the next-generation biomanufacturing market?
• What are the key players of the global next-generation biomanufacturing market, and what is their role in the market? Who are the leading payers in the single-use bioreactor market?

Market Overview

Biomanufacturing is the process of production of commercially important biomolecules by utilizing biological systems for use in medicines, food and beverage processing, and industrial applications. Natural sources such as blood, cultures of microbes, animal cells, or plant cells are often employed to carry out biomanufacturing. Cells used in the production process can also be derived using genetic engineering techniques.

The research study titled “Global Next-Generation Biomanufacturing Market” is focused on understanding the key trends of next-generation biomanufacturing with the use of single-use bioreactors and digital bioreactors across the globe.

The research study demonstrates the competitive landscape of the global next-generation biomanufacturing market and presents the market dynamics as well as the regulatory framework affecting the growth of the next-generation biomanufacturing across different regions.

The study also presents an in-depth analysis of the drivers, challenges, and opportunities of the market playing a significant role in major countries of North America, Europe, Asia-Pacific, Latin America, and the Rest-of-the-World.

The report is segmented based on workflow and product, medical application, end user, and region, thoroughly represented in different chapters. Each chapter provides a clear understanding of the products existing in the global next-generation biomanufacturing market and the current key trends in each domain.

The chapter further mentions the key companies of each domain and represents their contribution to the market. The report study also provides a holistic view of 15 major companies playing a key role by contributing their next-generation biomanufacturing market products.

In addition, the report covers detailed information on the advent of automation in biomanufacturing with data on types of automation, current trends, and opportunities in the field of automation.

Our healthcare experts have found global next-generation biomanufacturing to be one of the most rapidly evolving markets. The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85% during the forecast period 2021-2031 and is expected to reach a value of $85,201.2 million in 2031.

The following report presents the reader with an opportunity to unlock comprehensive insights regarding the next-generation biomanufacturing market and helps form well-informed strategic decisions.

The market research study also offers a broad perspective of the different types of products and services available in the market and their impact on the biomanufacturing industry by providing critical insights into the direction of its future expansion.

Within the research report, the market is segmented based on workflow and product, medical application, end user, and region. Each of these segments has been further categorized into sub-segments to compile an in-depth study.

Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

The global next-generation biomanufacturing market, by workflow, is primarily dominated by upstream biomanufacturing. This is mainly attributed to the involvement of a large number of high-cost equipment in upstream biomanufacturing compared to downstream biomanufacturing.

However, downstream biomanufacturing is expected to witness a high CAGR during the forecast compared to upstream biomanufacturing. This is mainly due to continuous product innovations in the chromatography product lines as well as in filtration systems used in downstream processing.

Among the different regions, North America dominated the global next-generation biomanufacturing market in 2020. Large, well-equipped biomanufacturing facilities with advanced infrastructure and strong investments in the biomanufacturing sector are significantly promoting the growth of the next-generation biomanufacturing market in North America.

Moreover, the ever-expanding biopharmaceuticals and biologics industry in North America is offering huge promises for the industry’s growth, attracting the attention of the investors attempting to enter this field.

Further, the headquarters of several key industry players in the U.S., such as Thermo Fisher Scientific, Inc., GE Healthcare, PBS Biotech, Inc., CESCO Bioengineering Co. Ltd., and Meissner Filtration Products, Inc., have further strengthened the market in the region.

Among all the regions, Asia-Pacific is expected to witness the highest CAGR during the forecast period 2021-2031. This is mainly attributed to the strong potential of emerging nations of Asia-Pacific, including Japan, India, Australia, South Korea, and Singapore, that are witnessing huge adoption of technologically advanced biomanufacturing equipment.

The growing surge in new capacity installations to meet the increased product demand in developing nations of Asia-Pacific is further expected to boost the next-generation biomanufacturing market growth.

Competitive Landscape

The next-generation biomanufacturing market is largely dominated by companies such as Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Guérin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd, Solaris Biotechnology Srl, Thermo Fisher Scientific Inc., ZETA GmbH.

The bioprocess segment of a few companies like GE Healthcare was highly impacted by the COVID-19 pandemic due to the supply-demand gap. Due to this, the company reported low segment revenue in 2020. However, key players like Danaher Corporation witnessed high growth in the revenue attributed to the high demand for bioprocess solutions products.

The global -next-generation biomanufacturing market is growing exponentially due to the high rate of investments from both public and private sectors for the development of facilities equipped with advanced biomanufacturing equipment and instruments.

Automation technologies are increasingly gaining prominence in the biomanufacturing industry over the years owing to their vast range of advantages in terms of greater speed, productivity, and accuracy. Offering a more streamlined and centralized control, the market for automation systems is growing rapidly, with a greater number of companies investing and launching new automation solutions in the market.

Over the past five years, from 2017 to 2021, the next-generation biomanufacturing market has witnessed around 115 key developments biomanufacturing and automation undertaken by key companies that varied from acquisitions to partnerships and collaborations, among others.

For instance, in February 2020, Honeywell International Inc. collaborated with Bigfinite, Inc. to contribute to process automation and controls technology with Bigfinite’s AI, data analytics, and machine learning platform to pace the medical therapies by helping pharma and biotech industries.

Further, in March 2019, Rockwell Automation and GE Healthcare underwent a collaborative agreement to combine their automation single-use solution expertise to build bioprocessing operations for digital bioprocessing.

Related:  Bioplastic Textiles Market : Global Analysis of Market Size, Share & Trends for 2019 – 2020 and Forecasts to 2030

The post Next-Generation Biomanufacturing Market – A Global Analysis: Focus on Single-Use and Digital Platform and Segment Analysis for Workflow, Products, Medical Application, End User, Country Data (16 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2031 first appeared on CRI Report.